Price (delayed)
$7.31
Market cap
$172.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.13
Enterprise value
$142.9M
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock
There are no recent dividends present for NVCT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.